Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease

Contributed by: Business Wire

Logo

Tags

Research

Finance

Neurology

Clinical Trials

Professional Services

Biotechnology

Pharmaceutical

Health

Science

Other Science

Phase 3b ADIP

More Like This

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins

Vertex Announces Key Advancements Across Kidney Portfolio

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

Bial Showcases Parkinson’s Research at MDS 2026

PR Newswire associated0

Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs